Fracture Incidence and Characterization in Patients on Osteoporosis Treatment: The ICARO Study

None of the available osteoporosis therapies have been shown to completely abolish the risk of fractures. In clinical practice, the outcome may be even poorer. In 880 patients prescribed with antiresorptives (alendronate, risedronate, and raloxifene) for >1 year, a fragility fracture was recorded in 8.9%/year of them. This incidence is considerably higher than that observed in randomized clinical trials, and it was significantly related to poor compliance and lack of supplementation with calcium and vitamin D.

[1]  Krista F. Huybrechts,et al.  The impact of compliance with osteoporosis therapy on fracture rates in actual practice , 2004, Osteoporosis International.

[2]  T. Spector,et al.  Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies , 2004, The New England journal of medicine.

[3]  E. Lewiecki.  Nonresponders to osteoporosis therapy. , 2003, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[4]  H. Genant,et al.  Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. , 2003, Bone.

[5]  S. Adami,et al.  Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors , 2003, Osteoporosis International.

[6]  Fran Harris,et al.  Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. , 2002, The American journal of medicine.

[7]  R. Marcus,et al.  Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. , 2002, Endocrine reviews.

[8]  D. Black,et al.  Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene Therapy , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[10]  D. Kiel,et al.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.

[11]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[12]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[13]  B. Ettinger,et al.  Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. , 1998, The American journal of managed care.

[14]  D. Hutchins,et al.  Patient Noncompliance with Hormone Replacement Therapy: A Nationwide Estimate Using a Large Prescription Claims Database , 1998, Menopause.

[15]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[16]  S. Cummings,et al.  The accuracy of self-report of fractures in elderly women: evidence from a prospective study. , 1992, American journal of epidemiology.

[17]  Min Jung Kim,et al.  US-Guided Vacuum-Assisted Biopsy of Microcalcifications in Breast Lesions and Long-Term Follow-Up Results , 2008, Korean Journal of Radiology.

[18]  O. Johnell,et al.  Mortality after osteoporotic fractures , 2004, Osteoporosis International.

[19]  G. Enzi,et al.  Medicine use and supplementation practice among participants of SENECA Study. , 2002, The journal of nutrition, health & aging.

[20]  J. Cauley,et al.  Risk of Mortality Following Clinical Fractures , 2000, Osteoporosis International.

[21]  Harry K. Genant,et al.  Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial , 2000 .

[22]  M. Hooper,et al.  Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.